4rnr › Citations

Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.

Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR
J Virol 89 1105-18 (2015)
Cited: 66 times
EuropePMC logo PMID: 25378488

Articles - 4rnr mentioned but not cited (2)

  1. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR. J Virol 89 1105-1118 (2015)
  2. Unveiling the multifaceted landscape of N-glycosylation in antibody variable domains: Insights and implications. Melo-Braga MN, Carvalho MB, Ferreira MCE, Lavinder J, Abbasi A, Palmisano G, Thaysen-Andersen M, Sajadi MM, Ippolito GC, Felicori LF. Int J Biol Macromol 257 128362 (2024)


Reviews citing this publication (20)

  1. Identification and specificity of broadly neutralizing antibodies against HIV. McCoy LE, Burton DR. Immunol Rev 275 11-20 (2017)
  2. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Bonsignori M, Liao HX, Gao F, Williams WB, Alam SM, Montefiori DC, Haynes BF. Immunol Rev 275 145-160 (2017)
  3. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Haynes BF, Wiehe K, Borrow P, Saunders KO, Korber B, Wagh K, McMichael AJ, Kelsoe G, Hahn BH, Alt F, Shaw GM. Nat Rev Immunol 23 142-158 (2023)
  4. HIV broadly neutralizing antibody targets. Wibmer CK, Moore PL, Morris L. Curr Opin HIV AIDS 10 135-143 (2015)
  5. Germline-targeting immunogens. Stamatatos L, Pancera M, McGuire AT. Immunol Rev 275 203-216 (2017)
  6. HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. de Taeye SW, Moore JP, Sanders RW. Trends Immunol 37 221-232 (2016)
  7. The HIV glycan shield as a target for broadly neutralizing antibodies. Doores KJ. FEBS J 282 4679-4691 (2015)
  8. Structural principles controlling HIV envelope glycosylation. Behrens AJ, Crispin M. Curr Opin Struct Biol 44 125-133 (2017)
  9. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Landais E, Moore PL. Retrovirology 15 61 (2018)
  10. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Crispin M, Doores KJ. Curr Opin Virol 11 63-69 (2015)
  11. Strategies to guide the antibody affinity maturation process. Doria-Rose NA, Joyce MG. Curr Opin Virol 11 137-147 (2015)
  12. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Griffith SA, McCoy LE. Front Immunol 12 708227 (2021)
  13. Antibody responses to the HIV-1 envelope high mannose patch. Daniels CN, Saunders KO. Adv Immunol 143 11-73 (2019)
  14. Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. Kepler TB, Wiehe K. Immunol Rev 275 129-144 (2017)
  15. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. Verkoczy L. Adv Immunol 134 235-352 (2017)
  16. The first 24 h: targeting the window of opportunity for antibody-mediated protection against HIV-1 transmission. Lewis GK. Curr Opin HIV AIDS 11 561-568 (2016)
  17. Targeting the N332-supersite of the HIV-1 envelope for vaccine design. Moyo T, Kitchin D, Moore PL. Expert Opin Ther Targets 24 499-509 (2020)
  18. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. Sun Z, Yan L, Tang J, Qian Q, Lenberg J, Zhu D, Liu W, Wu K, Wang Y, Lu S. Virus Res 243 75-82 (2018)
  19. HIV-1 Envelope Glycosylation and the Signal Peptide. Lambert GS, Upadhyay C. Vaccines (Basel) 9 176 (2021)
  20. Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases. Tang AF, Enyindah-Asonye G, Hioe CE. Vaccines (Basel) 9 112 (2021)

Articles citing this publication (44)

  1. Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N, Seabright GE, Kramer HB, Spencer DI, Royle L, Lee JH, Klasse PJ, Burton DR, Wilson IA, Ward AB, Sanders RW, Moore JP, Doores KJ, Crispin M. Cell Rep 14 2695-2706 (2016)
  2. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA, Wickramasinghe L, Ramos A, Bian CB, Simek M, Allen S, Karita E, Kilembe W, Lakhi S, Inambao M, Kamali A, Sanders EJ, Anzala O, Edward V, Bekker LG, Tang J, Gilmour J, Kosakovsky-Pond SL, Phung P, Wrin T, Crotty S, Godzik A, Poignard P. PLoS Pathog 12 e1005369 (2016)
  3. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Aussedat B, Walkowicz WE, Hwang KK, Saunders KO, Zhang R, Gladden MA, Monroe A, Kumar A, Xia SM, Cooper M, Louder MK, McKee K, Bailer RT, Pier BW, Jette CA, Kelsoe G, Williams WB, Morris L, Kappes J, Wagh K, Kamanga G, Cohen MS, Hraber PT, Montefiori DC, Trama A, Liao HX, Kepler TB, Moody MA, Gao F, Danishefsky SJ, Mascola JR, Shaw GM, Hahn BH, Harrison SC, Korber BT, Haynes BF. Sci Transl Med 9 eaai7514 (2017)
  4. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, Winstone H, Pickering S, Galao RP, Dupont L, Lista MJ, Jimenez-Guardeño JM, Laing AG, Wu Y, Joseph M, Muir L, van Gils MJ, Ng WM, Duyvesteyn HME, Zhao Y, Bowden TA, Shankar-Hari M, Rosa A, Cherepanov P, McCoy LE, Hayday AC, Neil SJD, Malim MH, Doores KJ. Immunity 54 1276-1289.e6 (2021)
  5. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. Pritchard LK, Harvey DJ, Bonomelli C, Crispin M, Doores KJ. J Virol 89 8932-8944 (2015)
  6. Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Barnes CO, Gristick HB, Freund NT, Escolano A, Lyubimov AY, Hartweger H, West AP, Cohen AE, Nussenzweig MC, Bjorkman PJ. Nat Commun 9 1251 (2018)
  7. Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. Behrens AJ, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M. J Virol 91 e01894-16 (2017)
  8. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, Walkowicz WE, Aussedat B, Wu NR, Cai F, Vohra Y, Park PK, Eaton A, Go EP, Sutherland LL, Scearce RM, Barouch DH, Zhang R, Von Holle T, Overman RG, Anasti K, Sanders RW, Moody MA, Kepler TB, Korber B, Desaire H, Santra S, Letvin NL, Nabel GJ, Montefiori DC, Tomaras GD, Liao HX, Alam SM, Danishefsky SJ, Haynes BF. Cell Rep 18 2175-2188 (2017)
  9. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Kong L, Torrents de la Peña A, Deller MC, Garces F, Sliepen K, Hua Y, Stanfield RL, Sanders RW, Wilson IA. Acta Crystallogr D Biol Crystallogr 71 2099-2108 (2015)
  10. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. Pritchard LK, Spencer DI, Royle L, Vasiljevic S, Krumm SA, Doores KJ, Crispin M. J Virol 89 6952-6959 (2015)
  11. Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. Krumm SA, Mohammed H, Le KM, Crispin M, Wrin T, Poignard P, Burton DR, Doores KJ. Retrovirology 13 8 (2016)
  12. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C. J Virol 91 e00828-17 (2017)
  13. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop. Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J. J Virol 90 3446-3457 (2016)
  14. Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ, Tang J, Sok D, Burton DR, Law M, Ward AB, He L, Zhu J. mBio 8 e00036-17 (2017)
  15. Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. Pantophlet R, Trattnig N, Murrell S, Lu N, Chau D, Rempel C, Wilson IA, Kosma P. Nat Commun 8 1601 (2017)
  16. The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection. Cortez V, Wang B, Dingens A, Chen MM, Ronen K, Georgiev IS, McClelland RS, Overbaugh J. PLoS Pathog 11 e1004973 (2015)
  17. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. Smith SA, Burton SL, Kilembe W, Lakhi S, Karita E, Price M, Allen S, Hunter E, Derdeyn CA. PLoS Pathog 12 e1005989 (2016)
  18. Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire. Williams KL, Wang B, Arenz D, Williams JA, Dingens AS, Cortez V, Simonich CA, Rainwater S, Lehman DA, Lee KK, Overbaugh J. Cell Rep 23 682-691 (2018)
  19. Defining HIV-1 Envelope N-Glycan Microdomains through Site-Specific Heterogeneity Profiles. Hargett AA, Wei Q, Knoppova B, Hall S, Huang ZQ, Prakash A, Green TJ, Moldoveanu Z, Raska M, Novak J, Renfrow MB. J Virol 93 e01177-18 (2019)
  20. Influence of protein/glycan interaction on site-specific glycan heterogeneity. Losfeld ME, Scibona E, Lin CW, Villiger TK, Gauss R, Morbidelli M, Aebi M. FASEB J 31 4623-4635 (2017)
  21. Assigning and visualizing germline genes in antibody repertoires. Frost SD, Murrell B, Hossain AS, Silverman GJ, Pond SL. Philos Trans R Soc Lond B Biol Sci 370 20140240 (2015)
  22. Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. Corrigan AR, Duan H, Cheng C, Gonelli CA, Ou L, Xu K, DeMouth ME, Geng H, Narpala S, O'Connell S, Zhang B, Zhou T, Basappa M, Boyington JC, Chen SJ, O'Dell S, Pegu A, Stephens T, Tsybovsky Y, van Schooten J, Todd JP, Wang S, VRC Production Program, Doria-Rose NA, Foulds KE, Koup RA, McDermott AB, van Gils MJ, Kwong PD, Mascola JR. Cell Rep 35 108937 (2021)
  23. Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. He L, Lin X, de Val N, Saye-Francisco KL, Mann CJ, Augst R, Morris CD, Azadnia P, Zhou B, Sok D, Ozorowski G, Ward AB, Burton DR, Zhu J. Front Immunol 8 1025 (2017)
  24. Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries. Han SY, Antoine A, Howard D, Chang B, Chang WS, Slein M, Deikus G, Kossida S, Duroux P, Lefranc MP, Sebra RP, Smith ML, Fofana IBF. Front Immunol 9 329 (2018)
  25. Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans. Zhang H, Fu H, Luallen RJ, Liu B, Lee FH, Doms RW, Geng Y. Vaccine 33 5140-5147 (2015)
  26. A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. Rubio AA, Filsinger Interrante MV, Bell BN, Brown CL, Bruun TUJ, LaBranche CC, Montefiori DC, Kim PS. J Virol 95 e0235020 (2021)
  27. Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies. Moyo T, Ferreira RC, Davids R, Sonday Z, Moore PL, Travers SA, Wood NT, Dorfman JR. Virology 501 12-24 (2017)
  28. Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity. Sutar J, Deshpande S, Mullick R, Hingankar N, Patel V, Bhattacharya J. PLoS One 16 e0251969 (2021)
  29. Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope Spike. Trattnig N, Blaukopf M, Bruxelle JF, Pantophlet R, Kosma P. J Am Chem Soc 141 7946-7954 (2019)
  30. Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. Wu NR, Nicely NI, Lee EM, Reed RK, Watts BE, Cai F, Walkowicz WE, Aussedat B, Jones JA, Eaton A, Trama AM, Alam SM, Montefiori DC, Haynes BF, Saunders KO. PLoS Pathog 15 e1008165 (2019)
  31. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Calado R, Duarte J, Borrego P, Marcelino JM, Bártolo I, Martin F, Figueiredo I, Almeida S, Graça L, Vítor J, Aires da Silva F, Dias I, Carrapiço B, Taveira N. Vaccines (Basel) 8 E171 (2020)
  32. Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. Shipley MM, Mangala Prasad V, Doepker LE, Dingens A, Ralph DK, Harkins E, Dhar A, Arenz D, Chohan V, Weight H, Mandaliya K, Bloom JD, Matsen FA, Lee KK, Overbaugh JM. Elife 10 e68110 (2021)
  33. Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies. Wei Q, Hargett AA, Knoppova B, Duverger A, Rawi R, Shen CH, Farney SK, Hall S, Brown R, Keele BF, Heath SL, Saag MS, Kutsch O, Chuang GY, Kwong PD, Moldoveanu Z, Raska M, Renfrow MB, Novak J. iScience 23 101711 (2020)
  34. Determinants of HIV-1 CD4-Independent Brain Adaptation. Shakirzyanova M, Kong XP, Cheng-Mayer C. J Acquir Immune Defic Syndr 76 209-218 (2017)
  35. Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies. van den Kerkhof TL, van Gils MJ, Boeser-Nunnink BD, Burger JA, Schuitemaker H, Sanders RW. AIDS 30 2179-2184 (2016)
  36. Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans. Huettner I, Krumm SA, Serna S, Brzezicka K, Monaco S, Walpole S, van Diepen A, Allan F, Hicks T, Kimuda S, Emery AM, IAVI Protocol C Investigators & The IAVI African HIV Research Network, Landais E, Hokke CH, Angulo J, Reichardt N, Doores KJ. Cell Rep 38 110611 (2022)
  37. Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. Ringe RP, Colin P, Ozorowski G, Allen JD, Yasmeen A, Seabright GE, Lee JH, Antanasijevic A, Rantalainen K, Ketas T, Moore JP, Ward AB, Crispin M, Klasse PJ. PLoS Pathog 19 e1011601 (2023)
  38. HIV Immunology Goes Out On a Limb. Doria-Rose NA, Mascola JR. Immunity 44 1088-1090 (2016)
  39. Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. Xu Z, Walker S, Wise MC, Chokkalingam N, Purwar M, Moore A, Tello-Ruiz E, Wu Y, Majumdar S, Konrath KM, Kulkarni A, Tursi NJ, Zaidi FI, Reuschel EL, Patel I, Obeirne A, Du J, Schultheis K, Gites L, Smith T, Mendoza J, Broderick KE, Humeau L, Pallesen J, Weiner DB, Kulp DW. Nat Commun 13 695 (2022)
  40. Myomedin replicas of gp120 V3 loop glycan epitopes recognized by PGT121 and PGT126 antibodies as non-cognate antigens for stimulation of HIV-1 broadly neutralizing antibodies. Daniel Lišková V, Kosztyu P, Kuchař M, Černý J, Bharadwaj S, Petroková H, Vroblová E, Křupka M, Malý M, Zosinčuková T, Šulc J, Rašková Kafková L, Raška M, Malý P. Front Immunol 13 1066361 (2022)
  41. A glycoside analog of mammalian oligomannose formulated with a TLR4-stimulating adjuvant elicits HIV-1 cross-reactive antibodies. Bruxelle JF, Kirilenko T, Trattnig N, Yang Y, Cattin M, Kosma P, Pantophlet R. Sci Rep 11 4637 (2021)
  42. Adjuvants influence the maturation of VRC01-like antibodies during immunization. Knudsen ML, Agrawal P, MacCamy A, Parks KR, Gray MD, Takushi BN, Khechaduri A, Salladay KR, Coler RN, LaBranche CC, Montefiori D, Stamatatos L. iScience 25 105473 (2022)
  43. Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana. Moraka NO, Choga WT, Pema MN, Chawawa MK, Gobe I, Mokomane M, Bareng OT, Bhebhe L, Kelentse N, Mulenga G, Pretorius Holme M, Mohammed T, Koofhethile CK, Makhema JM, Shapiro R, Lockman S, Moyo S, Gaseitsiwe S. Sci Rep 13 18134 (2023)
  44. Synthetic Neoglycoconjugates of Hepta- and Nonamannoside Ligands for Eliciting Oligomannose-Specific HIV-1-Neutralizing Antibodies. Cattin M, Bruxelle JF, Ng K, Blaukopf M, Pantophlet R, Kosma P. Chembiochem 23 e202200061 (2022)


Quick links